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Abstract. 
Thyroid hormones are critical to growth and development of the human fetus. In 
particular, the fetal central nervous system is extremely sensitive to the actions of the 
active ligand, tri-iodothyronine (T3).  The placenta is the organ during pregnancy that 
allows transport between the mother and her baby by close interaction of the maternal 
and fetal circulations. Endogenous fetal thyroid hormone production does not occur 
until the beginning of the second trimester. However, there appears to be 
transplacental transport of thyroid hormones to the fetus earlier in gestation and 
organs, such as the central nervous system, appear to be exquisitely sensitive to their 
actions.  The content of this Thesis describes my work, published in peer reviewed 
papers over the last fifteen years. It outlines the molecular mechanisms controlling the 
delivery and actions of thyroid hormones to the fetus. 
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1.1   Introduction. 
The link between perinatal brain development and thyroid dysfunction through iodide 
deficiency has been known for over a hundred years (McCarrison, 1908). 
 
Normal fetal development requires the presence of active thyroid hormone (both in the 
mother and fetus). Disruption of any of the processes regulating the bioavailability of 
thyroid hormone, or indeed its cellular interaction may contribute to abnormal fetal 
development (Kester et al. 2001). 
 
This thesis will focus upon my work over the last fifteen years exploring the molecular 
apparatus for thyroid hormone action, the factors controlling bioavailability of the 
‘active’ ligand to the human fetus and the effects of in-utero disease, particularly 
intrauterine growth restriction (IUGR). 
 
The placenta is a highly specialised organ, the primary function of which is to facilitate 
the passage of nutrients, gases and waste products between the maternal and fetal 
blood. In human pregnancy, placentation is haemochorial providing direct contact, in an 
intimate fashion, between the maternal circulation and the chorionic (fetal) villi. 
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Malplacentation, which in human pregnancy is associated with partial or complete 
failure of extravillous trophoblast (EVT) to invade and remodel the maternal 
‘uteroplacental’ spiral arteries by mid-pregnancy, is associated with relatively poor 
pregnancy outcome (Avagliano et al.2011). This ranges from IUGR, a condition where 
the fetus does not achieve its growth potential and is associated with significant 
perinatal morbidity (Avagliano et al.2011) to perinatal death (Cross 2006) 
 
Thyroid hormones are synthesised in the thyroid gland. Iodide from the diet is actively 
taken up into follicular cells in the thyroid gland by the sodium iodide symporter (pump) 
and is converted to iodine. Tyrosine becomes coupled to form pre-thyroglobulin. 
Coupling of mono-iodothyronine (T1) and di-iodothyronine (T2) form tri-iodothyronine 
(T3) and thyroxine (T4), which are stored in the colloid. Thyroid hormones are secreted 
in response to the binding of thyrotrophin (TSH) to a transmembrane receptor linked to 
a G-protein second messenger system (Hennemann and Visser.1997). 
 
Proportionally, more T4 than T3 is released into the circulation (in a ratio of 4:1). 
However T4 is converted to the active ligand T3 by peripheral tissues. In plasma, more 
than 99% of all T3 and T4 are bound to hormone binding proteins and only unbound 
ligand is available for cellular uptake (Friesema. 2001). 
 
1.2.  Thyroid receptors and their isoforms. 
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The majority of actions of thyroid hormone are mediated through the binding of the 
ligand T3, through its binding to nuclear receptors (thyroid receptors [TR]) (Evans et al. 
1988). 
 
Ligand binding studies have revealed the presence of high affinity nuclear binding sites 
for T3 in numerous human tissues (Oppenheimer et al. 1997). Two TR genes have been 
described and designated α and β (based on sequence similarities and chromosome 
localisation). The TRα1 and TRβ1 variants are known to bind T3, and through interaction 
with the T3 response elements, regulate transcription of specific genes (Lazar 1993; Yen 
2001). The ‘non-binding’ α2 variant may inhibit the function of the other ligand binding 
isoforms. The two TRα and the TRβ are ubiquitously expressed but an alternate splicing 
product of the β-gene, termed β2, is expressed in significant amounts only in the 
anterior pituitary gland and hypothalamic areas of the CNS (Nakai et al. 1988). 
 
1.3  Thyronine deiodinase subtypes. 
The availability of the active ligand T3 for local tissue receptor binding is determined, at 
least in part, by the activity of three selenocysteine monodeiodinase enzymes: 
deiodinase subtypes 1 (D1 or type I), 2 (D2 or type II) and 3 (D3 or type III). The 
deiodinases are integral membrane proteins located on the endoplasmic reticulum (ER) 
or external plasma membrane where the active site is exposed to cytoplasm. T4 is 
converted by outer ring deiodination (ORD) to the active ligand T3 or by inner ring 
deiodination (IRD) to the inactive metabolite, reversed T3 (rT3) (Visser 1988). Although 
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concentrations of rT3 may be relatively significant in the fetus, it does not form a 
binding ligand for the thyroid hormone receptors. T3 and rT3 are further deiodinated by 
IRD and ORD respectively to 3,3’-T2.  
 
Deiodinase type 1 (D1) catalyses both ORD and IRD and is expressed in human adult 
liver, kidney and thyroid gland (Kester 2001). D1 is the main enzyme for plasma T3 
production and plasma rT3 clearance in adults. Deiodinase type 2 (D2) has only ORD 
activity and thus converts T4 solely to active T3. In human adults it is mainly expressed 
in the CNS and pituitary gland. In addition, it is expressed in neonatal ‘brown’ adipose 
tissue. However mRNA encoding D2 has also been noted to be expressed in human 
cardiac and skeletal muscle (Kester 2001). 
 
Deiodinase type 3 (D3) has only IRD activity. In humans, it has been found to be 
expressed in the CNS and placenta. It is important in the inactivation of both tissue and 
plasma T3 as well as the production of rT3. 
 
Besides deiodination, conjugation reactions of glucouronidation and sulfation facilitate 
urinary and biliary excretion of thyroid hormones (Kester 2001). 
 
1.4.  Thyroid hormone transporters. 
Historically, it was believed that thyroid hormones, lypophilic molecules, pass through 
the lipid bilayer of the plasma membranes by passive diffusion. However, it is now 
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known that specific transport mechanisms exist for both uptake and export of thyroid 
hormones in cells.  
 
In-vitro evidence from cultured human hepatocytes has demonstrated an ‘energy-
dependency’ of thyroid transport (James et al. 2007). In 1986, a monochromal antibody 
raised against rat hepatocytes was noted to inhibit the uptake of both T4 and T3. This 
action was identified as a putative 52KD thyroid hormone transporter protein (Mol et al. 
1986).  Since this time, several proteins from a wide variety of tissues have been 
characterised as specific thyroid hormone transporters. These proteins belong to several 
‘families’, each of which has its own tissue specificity and is briefly outlined below.  
 
The Na+/tautochlorate co-transporting polypeptide (NTCP), a major transporter of 
conjugated bile acids across biliary duct cells, has also been found to be associated with 
Na+-dependent transport of iodothyronines (Friesema et al. 1999). Iodothyronines are 
organic anions and transported by the organic anion transporting polypeptide (OATP) 
family. This comprises a large group of multispecific proteins that have been 
demonstrated to be responsible for the transport of several amphipathic organic 
compounds in multiple tissues. Several members of this OATP ‘family’ have been 
demonstrated to transport thyroid hormone (Friesema et al.2005). 
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As the structure of the iodothyronines is based upon the ‘linkage’ of two tyrosine 
residues, amino-acid transporters have been examined for their potential also to 
transport thyroid hormones 
 
The L-type or system L amino-acid transporters have been demonstrated to transport 
large, neutral, branched chain amino-acids as well as thyroid hormones (Blondeau et al. 
1993; Zhou et al. 1990). 
 
In addition, specific transports for the amino acids tyrosine (Tyr), phenylalanine (Phe) 
and tryptophan (Trp), the so called ‘T-type’ transporters have also been noted to be 
involved in the transport of thyroid hormones (Zhou et al. 1992).  
 
One such transporter, human T-type amino acid transporter 1 (TAT1) has been cloned 
and expression studies have demonstrated that it transports Phe, Tyr and Trp but not 
iodothyronines (Kim et al. 2001). More recent specific characterisation of this 
transporter has subsequently noted that this protein, largely expressed in placental 
tissue, does in fact play a role in thyroid hormone into and across such tissue (Friesema 
et al. 2006). 
 
TAT1 demonstrates homology with members of the monocarboxylate transporter (MCT) 
family. This aforementioned protein has recently been classified and re-named MCT10. 
It is closely related to the MCT8 transporter. The MCT8 transporter has been 
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characterised and found to be a specific and potent thyroid hormone transporter, which 
again potentially facilitates the direct action of thyroid hormones on tissues that play a 
vital role in fetal brain development. The role of these two isoforms of the MCT 
transporter family, MCT8 and MCT10 has formed the basis of much of my group’s work 
over the last five years.  
 
1.5.  Transplacental passage of maternal thyroid hormones to the developing fetus. 
The importance of thyroid hormone in brain maturation and development has been 
demonstrated in clinical studies in iodine deficient areas of the world (such as China) 
(Delange and Ermans. 1996), as well as in elegant animal models (Morreale de Escobar  
et al.  1994). 
 
In the human fetus, TRH may be detected in the hypothalamus by the end of the first 
trimester (13 weeks), at a time when the thyroid gland begins to concentrate iodine. It is 
possible to measure TSH in the fetal pituitary and serum in early pregnancy, with 
concentrations rising towards term and often exceeding adult levels (Fisher et al. 1997a; 
Thorpe-Beeston et al. 1991a). Concentrations of total T4 and T3 in fetal serum have 
been described as rising between the 10th to 30th weeks of gestation in human 
pregnancy, paralleled by rising thyroxine binding globulin (TBG) levels.  
 
The use of fetal blood sampling by cordocentesis from the second trimester has noted 
an increase in free T4 and free T3 concentrations with increasing gestational age, 
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although these levels remain lower than corresponding thyroid hormone concentrations 
reported in the maternal circulation (Thorpe-Beeston et al. 1991a; Kilby et al. 1998). 
 
Classically it has been believed that the placenta allows little maternal thyroid hormones 
to cross to the developing fetus. However, investigations of the human fetus (prior to 
surgical termination of pregnancy) in the first trimester has indicated that coelomic 
puncture under ultrasound-guidance to obtain embryonic fluid, demonstrated the 
presence of human thyroid hormones at  in the early first trimester (5-8 weeks) before 
endogenous fetal thyroid hormone production occurs (Calvo et al. 1992; Calvo et al. 
2002).  
 
The clinical association of maternal hypothyroxaemia during the first trimester and 
neurological and intellectual impairment (including neuromotor anomalies) in the 
endemic cretin is well described (Halpern et al. 1991. However in the 1990’s, attention 
was focussed upon relatively mild (perhaps subclinical) neuropsychomotor deficits in 
babies born to women who in pregnancy had only mild iodine deficiency (Hetzel and 
Dunn. 1989). 
 
Pop and his group (1995) described an association between mothers who at 32 weeks 
gestation were known to have circulatory thyroperoxidise (TPO) antibodies and lower  
intelligence quotient (IQ) assessments in offspring (assessed by the general cognitive 
scale) than  in offspring of  mothers who had no circulatory TPO antibodies in 
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pregnancy. At this time the pathophysiological mechanism underlying this observation 
was that the presence of TPO antibodies led to a reduction in maternal thyroid 
hormones at this gestation (Lazarus. 1999). 
  
Thyroperoxidase antibodies are found relatively frequently in women of reproductive 
age and thus in early pregnancy.  A recent systematic review of the literature noted that 
in 18 studies performed over the last 30 years (in 10 countries), the prevalence of TPO 
antibodies ranges from 5 – 19.6% (Glinoer. 2008). These may have an action in terms of 
lowering circulating free T4 and T3 concentrations but may also indicate a generalised 
increase in ‘autoimmune’ activity.  Certainly, the presence of these antibodies appears 
to be associated with worsening perinatal outcome (Glinoer. 2008; Thangaratinam et al. 
2011).  The mechanism of this morbidity is presently unknown. 
 
Two papers published in the late 1990s led to an explosion of interest in the perinatal 
influence of maternal thyroid hormone metabolism and subsequent 
neurodevelopmental outcome in offspring.  This interest remains influential today.  
 
Haddow et al (1999) described a retrospective case-controlled study of sixty two 
singleton offspring identified on the basis of their mothers’ increased TSH level in the 
early second trimester. Although it was described that the pregnant women had 
subclinical hypothyroidism (SCH), it was subsequently noted that a proportion (18 of the 
62), with the mildest elevations in TSH, also had low total thyroxine concentrations, 
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making biochemical overt hypothyroidism (OH) a possibility. This aside, the 
infants/children subsequently underwent neurological/psychological evaluation 
between ages 7-9 years. The mean IQ of children born to untreated women in 
pregnancy (n=48) was 7 points lower than controls. A much larger proportion of 
offspring in the untreated hypothyroid cohort had IQs < 85 compared to treated 
controls (19% versus 5%). The offspring of the treated but still biochemically 
hypothyroid women (n=14) demonstrated no difference in IQ from controls. This led to 
researchers in the USA to postulate that these women were actually euthyroid in early 
pregnancy at a gestation when maternally-derived thyroid hormone (thyroxine) might 
be important. A subsequent follow up to this ‘sentinel’ paper demonstrated an inverse 
association between severity of maternal total T4 concentration and IQ of offspring 
(Klein et al.  2001).  
 
Almost simultaneously in Europe (the Netherlands), Pop and colleagues (1999) assessed 
infant neurodevelopment at 10 months of age in 220 apparently healthy children from 
‘uncomplicated’ pregnancies (Pop et al. 1999). Significantly lower psychomotor 
development indices were noted in 22 children born to women with free T4 
concentrations below the 5th percentiles (as measured at 12 weeks gestation). In those 
with FT4 concentrations >10th centile significantly higher psychomotor developmental 
indices were noted at 10 months. In a proportion of the women with overt biochemical 
hypothyroxaemia (with normal TSH), TPO antibodies were also often detected (Pop et 
al.1995).  
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It was these publications that led to the significant body of work summarised in this 
thesis and describing the biochemical and molecular thyroid hormone ‘apparatus’ in 
human placenta and the developing human fetal brain. Subsequent observational 
studies addressing subclinical hypothyroidism in pregnancy have reported mixed results; 
although many of these studies have small sample sizes, retrospective design and 
relatively short follow up periods of study (Radetti et al. 2000; Smit et al. 2000; Okon et 
al. 2009; Li et al. 2010). 
 
1.6. Intrauterine growth restriction. 
As has been indicated, IUGR is associated with significant perinatal morbidity and indeed 
mortality. In the prospective study described by my group, we utilised ultrasound to 
biometrically define IUGR (as outlined by other authors: Chang et al. 1993). IUGR was 
prospectively defined as an abdominal circumference (AC) of < 10th centile for gestation 
and a reduction in fetal growth velocity as defined as Δ AC of < one standard deviation 
in 14 days. In addition there was oligohydramnios (reduced amniotic fluid as defined as 
maximal pool depth < 10th centile) and increased impedance or pulsatility index (PI) in 
the umbilical artery circulation (a significant proportion having absent end diastolic 
velocity). This cohort of babies may have significant long term morbidity with up to 10% 
having neurodevelopmental morbidity and neurologic sequlae (Gaffney et al. 1994). 
Prospective follow up of surviving infants has demonstrated that up to 5% have 
significant neurodevelopmental delay at 9 years of age (Kok et al. 1998). Thyroid 
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hormone status is one of several factors that have been postulated to play a critical role 
in the pathogenesis of such morbidity, especially with respect to the growth and 
development of the fetal and childhood CNS (Fisher and Klein. 1981). 
 
1.7.  Thyroid hormone metabolism and intrauterine growth restriction. 
When fetuses noted to be ‘small for gestational age’ were investigated by fetal blood 
sampling, hypoxaemia and acidosis were noted.  In addition, low concentrations of free 
T4 and T3 were also noted in conjunction with modest elevations in TSH concentration 
(Thorpe-Beeston et al. 1991b). Our own group investigated a cohort of severely growth 
restricted fetuses (with up to 76% mortality in the perinatal period) in the late second 
and early third trimesters of human pregnancy.  Again, fetal serum free T3 and free T4 
concentrations were significantly lower (than appropriately grown and gestationally 
matched fetuses), although the serum TSH was not significantly different (Kilby et al. 
1998). 
 
Likewise, collection of umbilical cord blood from very low birth weight babies (VLBW) at 
delivery has revealed significant reductions in total T3 and T4 concentrations. This has 
been postulated as being secondary to reductions in TBG concentrations; as the free 
thyroid hormone concentration in umbilical cord blood was not significantly reduced 
(compared to appropriately grown ‘term’ babies) (Klein et al. 1997). In addition, 
‘transient’ hypothyroxaemia, characterised as low total and free thyroxine 
concentrations, with or without an elevation in TSH, is frequently associated with small 
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for gestation, premature neonates in the first month of postnatal life (Fisher. 1997a; 
Fisher. 1997b). Whilst treatment of permanent and ‘transient’ primarily hypothyroidism 
(associated with an elevated TSH) is considered important in terms of long-term 
neurological outcome, the significance of hypothyroxaemia of prematurity (with no rise 
in TSH) remains controversial (Oppenheimer and Schwartz. 1997), as does thyroxine 
replacement in this situation.  
These data have led my group of clinical and basic scientists to investigate the 
mechanism of thyroid hormone action and metabolism in the human placenta and fetal 
CNS in uncomplicated and IUGR pregnancies.  
 
Summary of work presented. 
2. Thyroid hormones and the placenta  
 
2.1. Thyroid hormone receptor expression in the human placenta and changes 
associated with IUGR. 
The expression of nuclear T3 binding to TRs was first described in placental 
homogenates using radio labelled techniques (Banovac et al. 1986). Such experiments 
were subsequently extended using cultured cytotrophoblasts demonstrating that the 
nuclear binding of radio labelled T3 was specific to this cell type (Nishii et al. 1989). 
 
Our relatively contemporary studies have refined and further added to data in the 
literature on this topic. We studied the expression of all TR isoforms in human placentas 
across gestation. Using semi-quantitative RT-PCR and increase in expression of TRα1, α2 
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and β2 transcripts were noted from the first to the third trimester of human pregnancy 
in whole placental homogenates. This was associated with a decline in mRNA encoding 
TRβ1 (Kilby et al. 1998). In addition, semi-quantitative immunohistochemistry defined 
nuclear expression of the isoforms TRα1, α2 and β1 (but not β2) being localised within 
the villous trophoblast and mesenchymal stromal core of the placental villi, which again 
increased with gestational age (Kilby et al. 1998).  Subsequently we went on to use laser 
capture microdissection (LCM) and quantitative Taqman RT-PCR to further define TR 
isoform expression in human ‘term’ placenta. These data again confirmed the 
expression of TRα1, α2 and β1 in syncytiotrophoblast and cytotrophoblasts layers (but 
not β2 isoform). However, the expression of these TRα and β isoforms appeared to 
increase in the heterogeneous stromal cells of the mesenchymal villous core’ compared 
to the trophoblast layer (Chan et al. 2004). 
 
These data in human pregnancy were in contrast to data relating to rat placenta. In 
these tissues between 16 and 22 days of gestation no change in mRNA encoding TRα1, 
TR β1, c-erbA α2 and c-erbA α3 was noted with advancing gestation (Leonard et al. 
2001). In addition, the maximal T3 binding capacity (Bmax) in nuclei extracted from 
placental homogenates doubled in the final half of gestation, indication that in rodents, 
TR binding activity is post-transcriptionally regulated, in contrast to human pregnancy. 
 
The demonstration (in human placental tissues) by my group, to describe a parallel 
increase in circulating fetal free thyroid hormone concentrations and placental  TRα1, 
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α2 and β1 expression apparently  supported the role of thyroid hormones in ‘target’ 
fetal tissues during development. Our work then focused on the effects of thyroid 
hormones on trophoblast (both cyto- and extravillous) function and differentiation 
(Kilby et al. 2005).  
 
In-vitro experiments of cultured first trimester cytotrophoblasts cells has previously 
been described, where increasing concentrations of T3 (10-6 – 10-8mol/l) increased the 
expression of immunoreactive epidermal growth factor (EGF), a cytokine reported to be 
important in trophoblast differentiation (Matsuo et al. 1993). These effects were 
described as being via the TRB, an effect attenuated by cycloheximide (5 X 10-5 mol/l), 
indicating that these effects were transcriptionally mediated (Maruo et al. 1991; Matsuo 
et al. 1993); Maruo et al. 1995).  This group also noted that ‘markers’ of cytotrophoblast 
differentiation- human chorionic gonadotrophin, human placental lactogen and 17β 
oestradiol, were increased with increasing concentrations of T3. 
 
My group also described endovascular, extravillous trophoblast, remodelling maternal 
spiral arteries in the first and second trimester placental bed, also expressed TR α and β 
isoforms on immunohistochemistry (Barber et al. 2005). 
 
These ‘expression studies’ in human placental tissues went on to provide a basis for our 
attempts to define the mechanisms by which T3 acts on human trophoblast and is 
summarised later in this thesis. 
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Comparisons of TR isoform expression between those in apparent uncomplicated 
human pregnancies and those complicated by severe prenatally-detected IUGR (as 
previously described) were made. Comparison of IUGR placental samples with those of 
gestationally-matched uncomplicated pregnancies revealed greater expression of TR α1, 
α2 and β1 variants in IUGR using semiquantitative immunohistochemistry. In contrast 
the mRNA encoding the TR isoforms were not differentially expressed when comparing 
IUGR and uncomplicated placentas (Kilby et al. 1998). It is postulated that the 
significantly lowered free T3 (and T4) in the circulations of fetuses with severe IUGR 
leads to an increased expression of TR α and β proteins in trophoblast nuclei.  
 
2.2.  Placental iodothyronine deiodinase subtype expression and changes associated 
with IUGR. 
The iodothyronine deiodinases are pre-receptor selenocysteine-containing enzymes that 
regulate local delivery of T3 (as described). Activities of all three iodothyronine 
deiodinase subtypes (D1, D2 and D3) have been demonstrated in rat placenta (Bates JM 
et al. 1999). However, in contrast to human pregnancy, rodent total serum T3 and T4 
increase with gestation and the predominant subtype expressed appears to be D3. 
 
My group, using placental biopsies from human pregnancy across gestation utilised 
quantitative Taqman RT-RCR, iodothyronine deiodinase activity assays and 
immunohistochemistry to describe the ontogeny of deiodinase subtypes in this human 
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tissue. The predominant deiodinase expressed in human placenta was type III (D3) 
(Chan et al. 2003), but type 2 (D2) was also expressed. In general terms, the activities of 
the enzymes D2 and D3 (and the mRNA encoding the genes to these enzymes) were 
higher earlier in gestation than at term; displaying an inverse relationship with 
advancing gestational age of the pregnancy. Our data were in agreement with Professor 
Theo Visser’s group which noted that although placental D2 and D3 activities 
(fmol/min/mg of placental tissue and thus corrected for protein) decreased with 
gestation (Koopdonk-Kool et al. 1996; Chan et al. 2003), the total activity (especially for 
D3) increases as the placental mass increases. There has been debate as to whether 
there is a functional significance to D2 activity in human placenta. Again, Visser’s group 
concluded that placental D2 activity was ‘hardly detectable’, being present 200 times 
lower than activity of D3 (Koopdonk-Kool et al. 1996). This was indeed the case in our 
group’s study (Chan et al. 2003). One may speculate that villous trophoblast D2 is less 
likely therefore to play a pivotal role in the homoeostatic modulation of fetal plasma 
T3/T4 but may play an autocrine/paracrine role, in that local generation of T3 within 
placenta and decidua may allow interaction with placental TRα and β isoforms) affecting 
trophoblast differentiation (Maruo et al. 1995). Such an effect is likely to be greatest at 
earliest gestations (Barber et al. 2005). 
 
As indicated, it is D3 that appears to have the greatest total activity in the human 
placenta. Teleologically, a hypothesis has been derived postulating that placental D3 
activity ‘protects’ the fetus from the relatively high concentrations of T4. 
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Our data are in accord with this theory, as in the first trimester, when the total placental 
surface area is relatively small, specific D3 activity is highest. In the third trimester 
(when total surface area is at its greatest), although specific D3 activity is relatively low 
(activity per mg placental weight), the total activity is increased (due to increasing 
placental size) and therefore this may increase T4 (in-)activation overall. This may 
increase physiologically the amounts of iodide passing through the human placenta to 
both the fetus and mother.   It is of interest that there have been reports that placenta 
from babies born with thyroid agenesis, and thus hypothyroidism, do not have 
significant alterations in placental D3 activity (Koopdonk-Kool et al. 1996). This therefore 
implies a constitutive modulation of these enzyme activities.  
 
In severe early onset IUGR, comparison of the relative expressions of mRNA encoding 
D2 and D3, in human placenta, as well as the activity of these enzyme subtypes, 
revealed no significant differences as compared to placenta of uncomplicated, 
gestationally-matched pregnancies (Chan et al. 2003). 
 
Interestingly, treatment of primary cultures of human ‘term’ cytotrophoblasts cells in-
vitro with increasing concentrations of T3 (1, 10 and 100nM) resulted in increased 
expression of mRNA encoding both D2 and D3; but only at a 100nM dose of T3, that is 
supraphysiological (Chan et al. 2003). 
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2.3. Expression of thyroid hormone transporters in human placenta and changes 
associated with IUGR. 
As previously indicated, plasma membrane transport of thyroid hormones has now been 
shown to require specific transporter proteins. This work has been supported by several 
grant giving bodies, notably the Medical Research Council and I have been a co-principal 
investigator on these grants. I freely acknowledge the collaborative nature of this 
portion of the work presented in this thesis with my colleague, the clinical scientist, Dr 
Shiao Chan (who I have worked with and mentored since she was a clinical PhD student 
appointed in 2000).  
 
We described the gestational autogeny of thyroid hormone transporters MCT8, MCT10, 
LAT1, LAT2, OATP1A2 and OATP4A1 in a relatively large series (n=110) of human 
placentas across gestation in uncomplicated pregnancies and their expression changes 
with IUGR (n=22). Quantitative, Taqman RT-PCR revealed that all the mRNAs encoding 
the aforementioned thyroid hormone transporters were expressed in human placenta 
from six weeks gestation onwards and throughout gestation. The transporters OATP4A1 
and CD98 (LATs obligatory associated protein) mRNA expression reached a nadir in mid-
gestation, before increasing towards ‘term’. LAT2 mRNA expression did not alter 
significantly with gestation. Our group also performed immunohistochemistry to localise 
MCT10 and OATP1A2 proteins to villous cytotrophoblasts and syncytiotrophoblasts (in 
villous placenta) and extravillous trophoblasts in the placental bed. In contrast, 
OATP4A1 appeared preferentially expressed in villous syncytiotrophoblasts (Loubiere et 
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al. 2010). Previously, we had noted the expression of MCT8 protein in human placenta 
(Chan et al. 2006). In first trimester placentas there was ‘focal’ immunoreactivity of 
MCT8 in villous cytotrophoblasts and syncytiotrophoblast. Particularly low immuno 
reactivity was noted in villous placenta in contact with the maternal circulation. MCT8 
protein expression appeared to increase in immunoreactivity towards the third 
trimester (Chan et al. 2006). Second trimester placental bed biopsies (from the 
Newcastle collection) demonstrated strong MCT8 protein localisation to decidual 
stromal cells (with no expression in decidual lymphocytes). Mononuclear and 
multinucleated interstitial trophoblast demonstrated variable MCT8 protein expression, 
whilst endovascular and intramural trophoblast cells demonstrated strong expression.  
 
In placentas from pregnancies complicated by severe IUGR (delivered in the early third 
trimester), MCT8 protein was increased (on Western immunoblots) (Loubiere et al. 
2010) a finding mirrored in mRNA encoding MCT8 (Chan et al. 2006), compared to 
placenta from gestationally-matched uncomplicated pregnancies. In contrast, mRNA 
encoding MCT10 transporter decreased in placental tissue of pregnancies complicated 
by IUGR. However, no change in mRNA or protein expression was noted in any other 
thyroid hormone transporters with IUGR. 
 
Thus, several thyroid hormone transporters are expressed in human placenta from the 
early first trimester. Their coordinated effects may aid local regulation of transplacental 
thyroid hormone passage and supply to trophoblast cells. Such action may be critically 
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important for the normal development of the human placenta and fetus (Chan et al. 
2009). 
 
2.4. The in-vitro effects of triiodothyronine on trophoblast function: differential 
responsiveness in normal and growth restricted pregnancies. 
I have already outlined in this synopsis some preliminary evidence that human 
trophoblast may be thyroid-responsive (Matsuo et al. 1991; Maruo et al. 1995). The 
relatively descriptive work performed and described to date has outlined that both 
villous and extravillous trophoblast have the ‘molecular apparatus’ to be thyroid-
responsive and potentially to regulate local T3 delivery allowing paracrine/autocrine 
responsiveness. 
 
In-vitro studies of human trophoblast derived cell lines and primary cultures  of 
cytotrophoblasts demonstrated that T3 epidermal growth factor (EGF) acted to exert 
antiproliferative effects on the extravillous-like cell line, SGHPL-4 (with the largest 
effects observed at low concentrations of both EGF [1 and 10ng/ml] and T3 [1 and 
10nm]). However, in contrast EGF and T3 exerted a proliferative response in JEG-3 
choriocarcinoma cells (increasing with increasing doses of EGF and T3) (Barber et al. 
2005). The proliferative response was increased using both uptake of tritiated thymidine 
and a methyltetrazoleum assay (MTT). 
 
 29 
EGF enhanced survival of non-proliferative ‘term’ cytotrophoblasts cells was also noted. 
However, T3 alone had no effect on MTT assay. The addition of T3 (up to 10nM) had no 
additional effects on EGF action on these cultured term cytotrophoblasts.  We were also 
interested to evaluate whether ‘in-vitro’ models simulating trophoblast invasion were 
affected by T3. EGF appeared to enhanced invasion significantly (as assessed by both 
length of and total number of invasive processes) of SGHPL-4 cells (EVT-like cells) into 
fibrin gel (maximal at EGF dose of 10ng/ml). This effect appeared to be attenuated by T3 
(at 1nM) (Barber KJ et al, 2005). Both T3 and EGF also significantly enhanced EVT-like 
cell motility, both independently and in combination (Barber et al. 2005). 
 
Recently, we have compared the T3 responsiveness and transport of primary 
cytotrophoblasts cells isolated from placentas of uncomplicated pregnancies (normal 
cytotrophoblasts) and those complicated by IUGR (gestationally matched).  Compared 
with normal cytotrophoblasts, the viability of IUGR cytotrophoblasts (assessed using the 
MT assay) were significantly reduced, whereas apoptosis (assessed using cleared 
caspase 3/7 activity and M30 immunoreactivity) was significantly increased after T3 
culture for 48hours (in trophoblast from both types of placenta).  The reaction of human 
chorionic gonadotrophin was significantly increased by IUGR cytotrophoblasts compared 
to ‘normal’ trophoblast. Net transport of [125I]T3 was 20% greater by IUGR 
cytotrophoblasts compared to normal cytotrophoblasts and this was accompanied by a 
two fold increase in expression of MCT8 protein (as assessed by Western 
immunoblotting) (Vasilopoulou et al. 2010). These data indicate an altered 
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responsiveness of cytotrophoblasts cultured from IUGR placenta to T3 with significant 
effects upon cell survival and apoptosis. Increased expression of MCT8 and T3 
(intracellular) accumulation may contribute to these observations (Vasilopoulou et al. 
2010). 
 
Finally, we investigated the effects of wild type (WT) MCT8 and a pathological mutant 
L471P on the growth and function of MCT8; null MCT8 expressing JEG cells. Transfection 
of WT MCT8 into JEG-3 cells increased T3 uptake but over expression of MCT8 in these 
cells attenuated cell proliferation (in the presence and absence of T3) in a dose-
dependant manner (James et al. 2009).  The data presented to date are focussed upon 
the potential action of T3 on trophoblast function and the mechanisms that potentially 
control transplacental delivery of thyroid hormones to the developing fetus.  
 
Epidemiological data indicates that the developing CNS in the human fetus may be 
exquisitely sensitive to the actions of thyroid hormone.  
 
The next part of this thesis outlines the data amassed by my group to define the 
molecular apparatus present in the human fetal brain that affect T3 sensitivity.  
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3. Human fetal CNS. 
3.1.  Thyroid hormone receptor isoforms: Expression in the fetal CNS and changes with 
IUGR. 
In the late 1990’s, I established a relatively large collection of first and second trimester 
(dated by ultrasound) fetal cerebral cortex samples obtained from surgical termination 
samples between 7-20 weeks gestation. This collection was established with approval of 
the local Research Ethics Committee (requiring written consent) and within the terms of 
the Polkinghorne recommendations and then more recently within the terms of the 
Human Tissue Act. In addition, fetal cerebral cortex and cerebellar samples were 
collected from stillborn babies, in the late second and third trimesters, both when the 
fetus was appropriately grown (n=21; gestational age [GA] 26-40 weeks) and 
complicated by IUGR (n=18; GA 23-39 weeks). Again appropriate research governance 
was in place for the collection of these human fetal tissues.  
 
RT-PCR revealed the presence of mRNAs encoding TRα1, β1 and β2 variants (although 
the latter was very week) and the non-functional TRα2 variant. Only the TRα1 mRNA 
expression was more abundantly expressed in fetal cerebral cortex than in adult 
cerebral cortical tissues (Kilby et al.2000; Chan et al. 2002). In contrast, TRα2 and TRβ1 
variants were expressed less abundantly than in adult tissues (Chan S et al, 2002).  
Messenger RNA encoding TRβ2 was weakly expressed in only 26% of fetal cerebral 
cortex samples.  
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Immunohistochemistry using antibodies against the TR isoforms was also performed in 
these fetal cerebral cortical samples and compared to adult samples (provided by the 
Queen’s Square neurological bank, London). Immunostaining of fetal cortex and 
cerebellum revealed significant TRα1 and TRα2 protein in nuclei from week 11 of human 
gestation (Kilby et al. 2000). Expression of all TR isoform proteins was largely confined to 
the nuclei of pyramidal neurons of the cerebral cortex and Purkinje cells of the 
cerebellum, with increasing receptor expression (percentage positive cells per high 
powered field) with advancing gestational age (Kilby et al. 2000). We performed a semi-
quantitative observer (unaware of the sample gestations or type) scoring. This 
demonstrated that the proportion of ‘immunopositive’ cell types increased with 
advancing gestation and by the second trimester there was a marked increase in the 
proportion of Pyramidal and Purkinje cells expressing TRα and β isoforms. By the third 
trimester, almost all cortical and cerebellar cells were immunostained (Kilby et al. 2000). 
These data confirmed the presence of TRα and β receptors, potentially capable of 
interacting with the active ligand T3 from early human pregnancy.  
 
In addition, comparison of TR immunostaining in human cerebral and cerebellar cortex 
from pregnancies complicated by IUGR (estimated fetal weight [customised by maternal 
BMI] of <10th centile for gestation) (n=18) noted significantly lowered intensity of 
immunostaining and the proportion of immunopositive cells in both cerebral cortex and 
cerebellum; as compared to gestationally-matched controls (Kilby et al. 2000). This was 
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confirmed using quantification using TR protein immunofluorescence and was so for all 
the TRα and β isoforms. 
 
3.2. Iodothyronine deiodinase subtype expression: ontogeny and with changes in 
IUGR. 
In the same human fetal cerebral cortex samples, my group used real time RT-PCR to 
quantify the expression of mRNA encoding iodothyronine deiodinase subtypes (D1, D2 
and D3). In addition, in collaboration with Professor Theo Visser’s group in Rotterdam, 
deiodinase subtype activities were also determined in these tissues and compared to 
adult cerebral cortex. Iodothyronine deiodinase mRNAs were expressed in human 
cerebral cortex from 7 weeks of gestation the expression of mRNA encoding D1 was 
variable in its expression with gestation but generally increased relative to adult cortex; 
whereas the D1 activity was below the level of assay detection.  Subtype deiodinase 
mRNA and protein activity was detectable in fetal cortex from 7 weeks (but not different 
from adult expression), and at 15-16 weeks, when expression was higher than in adults.  
Fetal cortex D3 mRNA expression was again present from the first trimester. The D3 
deiodinase enzyme activity appeared great at all gestations in fetal cortex compared to 
adults, reaching a zenith between 11-16 weeks (Chan et al. 2002).  
 
These data described the expression of TRα and β isoforms and the deiodinase subtypes 
in human cerebral cortex. These data where some of the first to describe the expression 
of molecules controlling T3 action at a cellular level in the human fetus.   However there 
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were limitations to this work, the most significant being that it was difficult to obtain 
sufficient intact human brain tissue to be able to describe the anatomical distribution of 
TR isoforms and deiodinase subtypes. Also in pathological human pregnancy there 
would be a variable direction between fetal death and post-mortem examination. This 
would lead to theoretical concerns relating to degradation in mRNA and protein. For this 
reason, I established a working collaboration with Professor Stephen Matthews at the 
University of Toronto to work with a guinea pig model to examine thyroid hormone 
receptor and deiodinase expression.  
 
3.3.  The effects of gestational maternal nutrient deprivation to induce in-utero fetal 
growth restriction in a guinea pig model. 
In guinea pigs, a 48 hour period of maternal nutrient deprivation at gestational day 50 
(term=70 days) resulted in fetal pups with hypothyroxaemia and increased brain/body 
weight ratios (indicative of IUGR). On gestational day 52 the guinea pigs were sacrificed 
and examination of the fetal brains using in-situ hybridization to localise and quantify 
mRNA encoding TRα1, α2 and β1, with neuroanatomical co-localisation of iodothyronine 
deiodinase D2 and D3 subtypes (Chan et al. 2005). 
 
With maternal deprivation, by day 52, TRα1 and β1 mRNA expression was significantly 
increased in male fetuses, but decreased in corresponding female hippocampus and 
cerebellum that demonstrated high TR expression under euthyroid conditions. Maternal 
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nutrition deprivation also resulted in increased mRNA encoding D2 in many areas of the 
fetal cortex in both sexes of offspring (Chan et al. 2005). 
 
Messenger RNA encoding D3 was only expressed in the fetal brains within the shell of 
the nucleus accumbens, the posterior amygdalohippocampal area, brain stem and 
cerebellum. This did not appear to be altered in maternal nutritionally-induced fetal 
growth restriction.  
 
These animal experiments demonstrated that material nutrient deprivation, inducing 
apparent IUGR, results in sex-specific changes in TRα and β mRNA expression, with a 
corresponding generalised increase in mRNA encoding D2 within the fetal brain. These 
observed changes may represent a ‘protective’ mechanism to maintain appropriate 
thyroid hormone action and delivery to the fetal brain in the face of relative fetal 
hypothyroxaemia (Chan et al. 2005). 
 
3.4. The expression of thyroid hormone transporters in the human fetal cerebral 
cortex during early development and their potential role in neuronal differentiation 
Associations of neurological impairment have been made with mutations in the thyroid 
hormone transporter, MCT8 (Schwartz and Stevenson. 2007). MCT8 is highly expressed 
in brain and is located in chromosome Xq13. Several mutations have been described 
mainly by the Visser (Friesema et al. 2004) and Refetoff (Dumitrescu et al. 2004) groups 
in the MCT8 gene, being responsible for the X-linked condition, Allen-Herndom-Dudley 
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syndrome. This is characterised by congenital hypotonia, progressive spasticity and 
neuropsychomotor delays associated with elevated serum levels of free T3, low levels of 
free T4 and TSH within the normal range. The mechanisms by which MCT8 in particular, 
but the thyroid hormone transporters in general, influence neural development have 
remained poorly defined.  
 
These data, produced by my group, go a small way to defining such roles. In many of the 
in-vitro experiments performed, we utilized NTERA-2 cl/D1 (NT2) cells. These are 
pluripotent embryonic cells from a line identified from a human teratocarcinoma and 
these cells exhibit similar biochemical and developmental characteristics of CNS 
precursor cells from the early human embryo (Chan et al. 2003). 
 
In the human fetal cerebral cortex (7-20 weeks gestation), compared to corresponding 
‘normal’ adult cortex, mRNA encoding OATP1A2, OATP1C1, OATP3A1 variant2, 
OATP4A1, LAT2 and CD98 were significantly reduced. This was in contrast to mRNA 
encoding MCT8, MCT10, and OATP3A1 variant 1 and LAT1, which demonstrated similar 
expression (Chan et al. 2011). Using immunohistochemistry, MCT8 and MCT10 protein 
was localised to the cerebral microvasculature.  
 
In-vitro culturing of NT2 cells (in T3 replete and depleted medium) and inducing 
neurodifferentation, demonstrated declining T3 uptake, accompanied by reduced 
expression of mRNA encoding MCT8, LAT1, CD98 and OATP4A1. In addition, T3 
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depletion of the culture medium significantly reduced MCT10 and LAT2 mRNA 
expression during neurodifferentation (but not associated with change in T3 uptake) 
(Chan et al .2011). 
 
NT2 retinoic acid induced-differentiation (either in T3 replete or deplete media) over 21 
days had no significant effect upon markers of neurodifferentiation, neurone lengths or 
numbers of branches (Chan et al. 2011).  We had previously noted that undifferentiated 
NT2 cells expressed mRNA encoding TRα and β isoforms and the deiodinase D2 and D3 
subtypes (Chan et al. 2003). In addition these cells express the thyroid responsive genes, 
myelin basic protein (MBP) and neuroendocrine specific protein A (NSP-A). As indicated 
above, these undifferentiated NT2 cells could be terminally differentiated over 5-6 
weeks. When terminally differentiated into post-mitotic neurons, TRα1 and β1 mRNA 
expression decreased by 74% and 95% respectively being associated with a 7-fold 
increase in NSP-A expression. Culturing the undifferentiated NT2 cells with increasing 
concentrations of T3 (at 10nM) led to a 2-fold increase in TRB expression and a 3-fold 
increase in D3 expression. In the terminally differentiated NT2 cells, T3 at 10nM led to a 
20% reduction in D3 mRNA expression.  
 
These data indicated that NT2 cells could be used as an in-vitro model of neuronal 
differentiation. These data demonstrated that undifferentiated NT2 are terminally 
differentiated cells demonstrating differing patterns of T3 responsiveness (Chan et al. 
2003).  
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Finally, we investigated the role of MCT8 expression on NT2 cell proliferation. We 
investigated the effect of wild-type (WT) MCT8 and the previously reported L471P 
mutant (Friesema et al. 2004) on the growth and function of the human neuronal 
precursor NT2 cells and (as previously mentioned in the placental section of the thesis) 
on MCT8-null JEG-3 choriocarcinoma cells. 
 
HA-tagged WTMCT8 correctly localised to the plasma membrane in NT2 cells and 
correspondingly increased T3 uptake (in NT2 and JEG-free cells). In contrast, L47IPMCT8 
mutant (associated with human newborn neurologic morbidity) was retained in the 
intracellular endoplasmic reticulum and displayed significant attenuation of T3 uptake 
(James et al. 2009).  Transient over expression of WTMCT8 and mutant MCT8 proteins 
failed to induce endoplasmic reticulum stress or apoptosis (James et al. 2009). However, 
MCT8 over expression significantly attenuated cell proliferation (as measured by MTT 
and thyrodine incorporation assays) in both the presence and absence of active T3. 
Finally, small interfering RNA depletion of endogenous MCT8 resulted in increased NT2 
cell survival and decreased T3 uptake (James et al. 2009). 
 
Given that T3 stimulated proliferation in undifferentiated NT2 cells, whereas MCT8 
repressed cell growth, these data suggest a novel role for this transporter, in addition to 
T3 uptake, mediated through the modulation of cell proliferation in the developing 
brain.   These data indicate that thyroid action on the developing fetal brain and the 
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intricate modular mechanisms controlling T3 cellular delivery are complicated and their 
actions may not be mediated through classical endocrine mechanisms. 
 
4. Future work: Beyond August 2011. 
At the time of writing this thesis work continues on the areas relating to the action of 
MCT8 and MCT10 transporters (both directly and in relation to thyroid hormone 
delivery) in the placenta. This focuses on a series of in-vitro experiments using primary 
cytotrophoblasts and extravillous trophoblast (from first and third trimester placentas) 
and utilising transient transfection and small interfering RNA depletion to affect MCT8 
(and MCT10) function in these cell types. These experimental designs are similar to but 
not identical to those described in our paper of 2009 (James et al. 2009) and will 
examine the effects of the thyroid hormone transporters in proliferation, 
differentiation, apoptosis and invasive potential. In addition, the primary 
cytotrophoblasts, extravillous trophoblast and explants are taken from both 
uncomplicated and complicated (by IUGR) pregnancies in and attempt to define 
aberrant physiology in these processes. 
 
We are also investigating the role of trophoblast and decidua interaction and the effects 
of thyroid hormone on implantation and placentation.  To help with this work we have 
collaborated with Dr Heike Hener in Jena, Germany to utilise both MCT8 null and 
heterozygous mice and to elucidate trophoblast function in these animals. My group 
continues to be interested in the potential role of exogenous thyroid hormone 
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replacement in potentially ameliorating adverse effects in human pregnancy associated 
with hypothyroxaemia and overt hypothyroidism.  
 
 To these ends, we have recently published a systematic review and critical appraisal of 
the literature investigating the effects of TPO antibodies in pregnancy when the women 
retain TSH within physiological range. Our systematic review includes data on 31 studies 
(12,126 women) relating to miscarriage and five studies (12,566 women) relating to 
preterm delivery. Meta-analysis of both the cohort (n=19) and case-controlled (n=12) 
studies demonstrated a positive association of TPO antibodies and miscarriage (OR 3.9; 
95%CI 2.48-6.12; p<0.001) for cohort studies and 1.8; 1.25-2.6 (p<0.002) in the case 
controlled studies (Thangaratinam et al. 2011). In addition, a doubling of the odds of 
premature delivery was also noted (OR 2.07; 98%CI 1.17-3.68). It was notable that the 
mean TSH concentration was significantly higher in the TPO antibody positive group 
than those without antibodies but pregnancy loss.  Furthermore, two relatively small 
randomised controlled trials have demonstrated in such circumstances that 
levothyroxine treatment leads to a significant reduction in miscarriage and preterm 
delivery (Thangaratinam et al. 2011). 
 
The MRC EME board has funded our collaborative group from this year to perform a RCT 
of sufficient power to draw from conclusions relating to treatment of TPO activity 
positive women in human pregnancy and also to determine the mechanisms by which 
thyroid antibodies may exert their detrimental effects.  
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5.  Conclusions 
There is increasing evidence that transplacental passage of maternal thyroid hormones 
is important in the development of the human CNS. A recent unpublished RCT of 
maternal thyroxine replacement in maternal hypothyroxaemia failed to demonstrate 
any significant difference in outcome. However, limitation of treatment was up to 16 
weeks of gestation, relatively late and after the time of endogenous fetal thyroid 
hormone production.  
 
Thyroid hormone deficiency or excess alters cell differentiation, migration and gene 
expression in the developing fetal brain and may have long term sequlae on 
neurodevelopmental morbidity. In addition, the placenta appears to have some thyroid 
hormone responsive properties. A well functioning placenta is essential for normal fetal 
development. IUGR is commonly associated with malplacentation and is a significant 
contributor to perinatal mortality and morbidity. It is postulated that the changes 
observed in the expression of thyroid hormone receptors, the pre-receptor deiodinase 
subtypes and transporters in human placenta and the developing fetal brain may be in 
response to the fetal hyperthyroxinemia present in this condition and affecting long 
term morbidity.  
 
The full papers that have been peer reviewed and published between 1998-2011. These 
are enclosed in Appendix 1. 
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7. Other works. 
 The main content of this DSc Thesis relates to my research focused upon thyroid 
hormone action on placental and fetal brain development.  However, since being 
appointed as a Senior Lecturer to the University of Birmingham in 1996, I have published 
peer review papers relating to other aspects of clinical fetal medicine and therapy (listed 
in Appendix II).  The broad subdivision of research work is divided into two areas: 
 
7.1.  Epidemiological, population based studies of outcomes on congenital anomalies. 
In collaboration with the West Midland’s Perinatal Institute, Congenital Anomaly 
Register (with Professor Jason Gardosi, Dr Michael Wyldes and Ms. Ann Tonks) I have 
been able to investigate and publish data relating to the epidemiology and fetal therapy 
/paediatric interventions on outcomes in congenital malformations.  This work has used 
population data bases recording pregnancy outcome on all pregnancies, as well as those 
that have congenital malformations.  Cross reference with our data base at the West 
Midlands Fetal Medicine Centre, regional cytogenetic laboratory, Birmingham Children’s 
Hospital and the regional neonatal intensive acre units has allowed us to look at 
outcomes including accurate outcomes for spontaneous fetal loss, stillbirth, neonatal 
and infant loss rates as well as those pregnancies in whom  termination of pregnancy is 
preformed.  This has allowed the accurate ‘mapping’ of pregnancy outcomes for 
individual congenital malformations.  This includes data as to whether the malformation 
is isolated or not, whether there is a coincidental chromosomal anomaly and the effects 
of fetal and neonatal therapy/intervention.  All these data are corrected for accurate 
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population-based ‘denominator’ data.  This has been performed for several of the major 
congenital malformations, including anterior abdominal wall defects, diaphragmatic 
hernia, severe cardiac malformations, including hypoplastic left heart syndrome and 
bladder neck obstruction.  Trends in incidence with time have been noted and these 
data allow both healthcare professional and parents to have prognostic information 
relating to perinatal outcomes.  
 
7.2.  Assessment of diagnostic and therapeutic interventions in fetal medicine. 
This work has focused upon several areas of diagnostic and therapeutic fetal medicine 
and therapy.  I worked with Professor Khalid Khan and his group to critically appraise the 
literature, using systematic reviews and meta-analysis of outcomes relating to fetal 
diagnostic tests and fetal therapy.  I have been fortunate, in that the West Midlands 
Fetal Medicine Centre is a supraregional referral centre (where I am clinical lead) and 
has a large throughput of babies with perinatal diseases that are potentially treatable.  
This has allowed me to publish data relating to relatively large cohort series on 
outcomes for fetal intervention and in many cases relate findings to population-based 
dominator data.   This has allowed the publication of cohort series relating to diagnostic 
tests in fetal anaemia, treatment of Rhesus disease by in-utero, intravascular transfusion 
and comparisons with outcomes by different techniques and experience of operator.  
Similarly, we have critically appraised the literature relating to outcomes of babies of 
monochorionic twins with complications; such as twin to twin transfusion syndrome and 
single twin demise. 
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Perhaps most successfully, my group completed a series of systematic reviews 
examining outcomes in babies with congenital bladder neck obstruction (where 
perinatal mortality is high from pulmonary hypoplasia and early renal failure). Our 
systemic review evaluating in-utero vesicoamniotic shunting led to the case for a 
international randomised controlled trial to evaluate such treatment, which was funded 
by the HTA (the PLUTO trial).  The results of this trial and being evaluated and will be 
published in early 2012. 
 
These two other bodies of work have significantly contributed to the literature in the 
field of fetal medicine and therapy and form a significant proportion of peer reviewed 
and published data in my name (as listed in Appendix II). 
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